The sofosbuvir plus ribavirin vs sofosbuvir plus daclatasvir in obtaining sustained viral response in chronic hepatitis c. | [Professional Medical Journal • 2023]

Author(s):

1. Malik Muhammad Waseem: Services Hospital, Lahore, Pakistan

2. Irfan Younus: Nawaz Sharif Medical College, Gujrat, Pakistan

3. Muhammad Habib: Mayo Hospital, Lahore, Pakistan

4. Adnan Qadir: Islamic International Medical College, Rawalpindi, Pakistan

5. Shahid Sarwar: SIMS, Lahore, Pakistan

6. Zameer Butt: Aziz Bhatti Shaheed Teaching Hospital, Gujrat, Pakistan

Abstract:

Objective: To compare the Sustained viral response (SVR) in patients who had taken Sofosbuvir plus Ribavirin for 24 weeks and Sofosbuvir plus Daclatasvir for 12 weeks to treat hepatitis C. Study Design: Randomized Control Trial. Setting: Medical Division of Mayo Hospital, Lahore. Period: One Year duration, 2021. Material & Methods: 130 patients of chronic Hepatitis C were divided into two categories based on whether they met the inclusion requirements. In Group A patients used sofosbuvir plus ribavirin for six months, whereas patients of Group B took sofosbuvir plus daclatasvir for 3 months. In order to determine SVR, PCR for HCV RNA Quantitative was done at week twelve after completion of the course. SPSS 23.0 was applied to enter and analyze the data. Results: All cases had an average age of 48.80 + 16.63 years, whereas it was 48.09 +16.43 years for group A and 49.51+ 16.92 years for groups B. In group A, there were 39 cases (60%) of men and 26 cases (40%) of women, while in group B, there were 34 instances (52.3% men and 31 cases (47.7% women). SVR was attained in 34 (52.34%) of group A participants and 54 (83.12%) of group B participants (p-value of 0.001). Conclusion: Sof+Dacla group had significantly high SVR than Sof+Riba group especially in non-cirrhotic and treatment-naïve individuals.

Page(s): 1574-1577

DOI: 10.29309/TPMJ/2023.30.12.7608

Published: Journal: Professional Medical Journal, Volume: 30, Issue: 12, Year: 2023

Keywords:

PCR , HCV , ribavirin , Daclatasvir , Sofosbuvir , Sustained viral response

References:

References are not available for this document.

Citations

Citations are not available for this document.

Citations

Downloads

Views